Abbott Laboratories (ABT) shares plunged to their lowest level in more than two decades after the healthcare giant delivered cautious 2026 guidance that fell short of Wall Street consensus, overshadowing an otherwise mixed quarterly performance. Abbott Laboratories (ABT) shares closed at $108.61, down $12.12, or 10.04%, at 4:01 p.m. EST. The sharp decline marked Abbott’s worst single-day drop in over 20 years and pushed the stock to a closely watched 52-week low, intensifying selling pressure from both institutional investors and short-term traders.
For full-year 2025, Abbott reported adjusted diluted earnings per share of $5.15, up 10% year over year, while GAAP diluted EPS came in at $3.72. In the fourth quarter, adjusted diluted EPS rose 12% to $1.50, compared with GAAP diluted EPS of $1.01.
Full-year 2025 sales reached $44.3 billion, representing 6.7% organic growth in the underlying base business, or 5.7% on a reported basis. Fourth-quarter revenue totaled $11.5 billion, reflecting 3.8% organic growth when excluding COVID-19 testing-related sales, or 4.4% reported growth, with performance led by Medical Devices and Established Pharmaceuticals.
While Abbott’s fourth-quarter results were not a complete miss, the forward-looking outlook proved to be the decisive factor behind the steep sell-off, reinforcing concerns about near-term earnings momentum.
However, revenue of $11.46 billion fell short of the roughly $11.8 billion forecast by the broader Wall Street consensus. That revenue miss, though modest on the surface, raised questions about demand trends across several of Abbott’s core business lines.
Investors appeared willing to look past the revenue shortfall initially, but sentiment quickly deteriorated as attention shifted to management’s outlook for 2026.
Nutrition Segment Emerges as the Core Weakness
The primary drag on results came from the Nutrition/Infant Formula segment, which experienced a significant volume decline during the quarter. Abbott cited heightened price sensitivity among consumers, particularly in pediatric nutrition, as inflation and competitive pricing pressured demand.
China emerged as a notable challenge, where volume-based procurement policies and intensified competition weighed heavily on sales. The Abbott nutrition revenue miss was especially concerning for investors, as the segment has historically provided steady, high-margin growth. Its underperformance became the central narrative behind the Abbott stock drop 2026.
Medical Devices and FreeStyle Libre Remain Bright Spots
Offsetting some of the weakness, Abbott’s Medical Devices / MedTech division delivered strong results, posting approximately 12.3% growth. The standout performer was Diabetes Care, led by the continued global adoption of the FreeStyle Libre glucose monitor.
Analysts largely agreed that FreeStyle Libre remains a durable growth driver and a key competitive advantage for Abbott. However, the market signaled that strength in Medical Devices alone is not sufficient to counterbalance sustained weakness in Nutrition.
Sentiment was further clouded by Abbott’s recently announced $21 billion acquisition of Exact Sciences Corp (EXAS). While management positioned the deal as a long-term growth opportunity that expands Abbott’s diagnostics portfolio, some investors expressed concern over integration risk and potential margin dilution.
The perceived Exact Sciences acquisition impact, combined with soft Nutrition trends, contributed to a broader reassessment of Abbott’s near-term earnings profile.
The decisive blow came with Abbott’s 2026 guidance, which forecast adjusted EPS of $5.55 to $5.80. Although the range technically overlaps with estimates, it undershot the analyst consensus of approximately $5.67 at the midpoint, creating a clear forecast gap.
Technical Breakdown Amplifies the Move
The sell-off pushed Abbott shares into the 105.79 – 113.90 range. Elevated trading volume suggested forced selling, and technical breakdowns amplified the decline. As traditional healthcare investors reassess their 2026 portfolios, many are diversifying into digital assets and exploring high-utility ecosystems, including the crypto casinos, which have seen a surge in popularity among tech-savvy traders looking for licensed and verified entertainment platforms.
For now, Abbott Laboratories faces heightened scrutiny. Until Nutrition stabilizes and confidence in 2026 earnings improves, investors appear cautious, despite the company’s strong Medical Devices franchise and long-term growth potential.
